These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10617402)

  • 1. Drug treatment of lipid disorders.
    Broeders N; Knoop C; Abramowicz D
    N Engl J Med; 1999 Dec; 341(26):2020-1. PubMed ID: 10617402
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
    Melenovsky V; Stulc T; Kozich V; Grauova B; Krijt J; Wichterle D; Haas T; Malik J; Hradec J; Ceska R
    Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homocysteine elevation with fibrates: is it a class effect?
    Harats D; Yodfat O; Doolman R; Gavendo S; Marko D; Shaish A; Sela BA
    Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrate-induced increase in blood urea and creatinine.
    Lipscombe J; Bargman JM
    Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
    [No Abstract]   [Full Text] [Related]  

  • 6. Deterioration in renal function associated with fibrate therapy.
    Goffin E; Devuyst O; Pirson Y
    Clin Nephrol; 2001 Jun; 55(6):490. PubMed ID: 11434364
    [No Abstract]   [Full Text] [Related]  

  • 7. Creatininemia during fibrate therapy: a reply to Lipscombe et al.
    Hottelart C; Achard JM; Fournier A
    Clin Nephrol; 2001 Jul; 56(1):85-6. PubMed ID: 11499666
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Dierkes J; Westphal S; Luley C
    Expert Opin Drug Saf; 2004 Mar; 3(2):101-11. PubMed ID: 15006716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current drug treatments for lipid management.
    Stone NJ
    Manag Care; 2002 Sep; 11(9 Suppl):4-9. PubMed ID: 12369341
    [No Abstract]   [Full Text] [Related]  

  • 11. Possible mechanisms of the fibrate-induced increase in serum creatinine.
    Tsimihodimos V; Miltiadous G; Bairaktari E; Elisaf M
    Clin Nephrol; 2002 May; 57(5):407-8. PubMed ID: 12036205
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cost-benefit analysis of the therapy of lipid metabolism disorders].
    Karádi I
    Orv Hetil; 1996 May; 137(21):1164. PubMed ID: 8757110
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?].
    Gironet N; Jan V; Machet MC; Machet L; Lorette G; Vaillant L
    Ann Dermatol Venereol; 1998 Sep; 125(9):598-600. PubMed ID: 9805549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of serious adverse events. Lipid-lowering therapy revisited.
    Wright JM; Puil L; Bassett CL
    Can Fam Physician; 2002 Mar; 48():486-9, 492-5. PubMed ID: 11935713
    [No Abstract]   [Full Text] [Related]  

  • 15. [Practice guidelines--disorders of lipid metabolism. From recommendations to therapy of disorders of lipid metabolism by the Drug Committee of the German Medical Society. Drug Committee of the German Medical Society].
    Z Arztl Fortbild Qualitatssich; 2000 Jan; 94(1):61-4. PubMed ID: 10721166
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety considerations with fibrate therapy.
    Davidson MH; Armani A; McKenney JM; Jacobson TA
    Am J Cardiol; 2007 Mar; 99(6A):3C-18C. PubMed ID: 17368275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
    McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE
    J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for lipid disorders.
    Treat Guidel Med Lett; 2003 Aug; 1(12):77-82. PubMed ID: 15529095
    [No Abstract]   [Full Text] [Related]  

  • 20. Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia.
    Baron M
    Health Care Food Nutr Focus; 2005 Jun; 22(6):7-11. PubMed ID: 15923907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.